Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey

CONCLUSION: Real-world data suggest that many healthcare professionals still do not easily prescribe HRT for gynecological cancer survivors and BRCA mutation carriers after RRSO. Further efforts are required to implement the use of HRT in clinical practice and to support both clinicians in recommending HRT and patients in accepting it.PMID:38497108 | DOI:10.3802/jgo.2024.35.e70

Source: Journal of Gynecologic Oncology - March 18, 2024 Category: OBGYN Authors: Innocenza Palaia Giuseppe Caruso Violante Di Donato Camilla Turetta Antonella Savarese Giorgia Perniola Roberta Gallo Andrea Giannini Vanda Salutari Giorgio Bogani Federica Tomao Diana Giannarelli Gabriella Gentile Angela Musella Ludovico Muzii Sandro Pig Source Type: research